Decoy Therapeutics
DCOY
4 hedge funds and large institutions have $31K invested in Decoy Therapeutics in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 2 closing their positions.
195% more capital invested
Capital invested by funds: $10.5K → $31K (+$20.5K)
0.51% more ownership
Funds ownership: 0.3% → 0.81% (+0.51%)
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$24.8K |
| 2 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$12 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.71K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3.21K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$268 |
| 4 |
Morgan Stanley
New York
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Capital Management
Malvern,
Pennsylvania
| $29K | +$24.8K | +4,034 | New |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $1.84K | -$4.71K | -765 | -75% |
|
|
3
UBS Group
Zurich,
Switzerland
| $180 | -$3.21K | -521 | -95% |
|
|
CIAM
4
Caitong International Asset Management
Hong Kong
| $14 | +$12 | +2 | New |
|
|
ASN
5
Advisory Services Network
Atlanta,
Georgia
| – | -$268 | -41 | Closed |
|
|
6
Morgan Stanley
New York
| – | -$7 | -1 | Closed |
|
DCOY Hedge Fund Activity: Q2 2026 in Review
4 of the 8,239 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q2 2026, worth a combined $31K — up 195% from $10.5K a quarter earlier.
Fund positioning in DCOY was balanced in Q2 2026: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Capital Management, opening a new position worth an estimated $24.8K. The largest seller was Tower Research Capital (TRC), cutting an estimated $4.71K.
- 4 institutional investors held Decoy Therapeutics (DCOY) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $31K of Decoy Therapeutics stock for Q2 2026, up 195% quarter-over-quarter.
- 2 funds opened new Decoy Therapeutics positions in Q2 2026 and 2 closed out, a net change of 0 holders.
- The largest Decoy Therapeutics buyer in Q2 2026 was Vanguard Capital Management, an estimated $24.8K added.
- The largest Decoy Therapeutics seller in Q2 2026 was Tower Research Capital (TRC), an estimated $4.71K sold.
Based on aggregated 13F filings for Q2 2026.